Omarigliptin

• Description :

  Omarigliptin (MK-3102) is a potent, selective, orally active and cross the blood-brain barrier dipeptidyl peptidase 4 (DPP-4) inhibitor. Omarigliptin shows anti-parkinsonian activity. Omarigliptin has the neuroprotective effect to improve diabetes-associated cognitive dysfunction[1][2][3].

• Product Name Alternative :

  MK-3102

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Dipeptidyl Peptidase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/Omarigliptin.html

• Purity :

  99.96

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  N[C@@H]1[C@@H](C2=CC(F)=CC=C2F)OC[C@H](N3CC4=NN(S(=O)(C)=O)C=C4C3)C1

• Molecular Formula :

  C17H20F2N4O3S

• Molecular Weight :

  398.43

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ayoub BM, et al. Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent. Sci Rep. 2018 Jun 12;8 (1) :8959. |[2]Li X, et al. Omarigliptin alleviates cognitive dysfunction in Streptozotocin-induced diabetic mouse. Bioengineered. 2022 Apr;13 (4) :9387-9396.|[3]Ayoub BM, et al. Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A2A Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain/Plasma Concentration Ratio after 28 Days Multiple Doses in Rats Using LC-MS/MS. Molecules. 2021 Feb 8;26 (4) :889.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  DPP-4

• CAS Number :

  [1226781-44-7]